Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Chemotherapy. Hôpital Ambroise Paré, Boulogne Cedex, France

Survival: 22.4 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: France
City/State/Province: Boulogne Cedex
Hospital: Hôpital Ambroise Paré
Journal: Link
Date: 4/2009

This study involved 52 patients with EGFR-detectable metastatic colorectal cancer. The median age of the patients was 61 years, and 63.5% were male.

Patients were treated with a biologic therapy cetuximab, which is a monoclonal antibody that targets the epidermal growth factor receptor protein on cancer cells and inhibits cell growth. In addition, patients were given a combination of the chemotherapy agents irinotecan, 5-fluorouracil, and folinic acid (this combination is sometimes referred to as FOLFIRI).

Grade 3 or 4 toxicities were reported for 65% of the patients, including leucopenia, rash, diarrhea, vomiting, and weakness.

The median overall survival was 22.4 months. The median progression-free survival was 7.9 months.

This study was partially supported by Merck KGaA, the makers of cetuximab (trade name Erbitux).

Correspondence: Dr. Philippe Rougier; email:

E-mail to a Friend Email Physician More Information